About Obsidian Therapeutics
Obsidian Therapeutics is a company based in Cambridge (United States) founded in 2015. It operates as a HealthTech. Obsidian Therapeutics has raised $325 million across 3 funding rounds from investors including Amgen, TD Securities and Citadel. The company has 80 employees as of December 31, 2022. Obsidian Therapeutics offers products and services including OBX-115 and cytoDRiVE® Platform. Obsidian Therapeutics operates in a competitive market with competitors including BeiGene, Serum Institute of India, Senti Biosciences, TScan Therapeutics and Vir Biotechnology, among others.
- Headquarter Cambridge, United States
- Employees 80 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Obsidian Therapeutics, Inc.
-
Annual Revenue
$639.91 (USD)-47as on Jul 31, 2023
-
Net Profit
$-612.02 (USD)-146as on Jul 31, 2023
-
EBITDA
-
Total Equity Funding
$325 M (USD)
in 3 rounds
-
Latest Funding Round
$160.5 M (USD), Series C
Apr 03, 2024
-
Investors
Amgen
& 24 more
-
Employee Count
80
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Obsidian Therapeutics
Obsidian Therapeutics offers a comprehensive portfolio of products and services, including OBX-115 and cytoDRiVE® Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
An investigational therapy for advanced melanoma treatment.
A platform for controlling therapeutic protein functions.
Unlock access to complete
Unlock access to complete
Leadership Team
23 people
Scientific Team
8 people
Product Management Team
7 people
Software Development Team
4 people
Finance and Accounting
3 people
Human Resources and Administration
2 people
Senior Team
2 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of Obsidian Therapeutics
Obsidian Therapeutics has successfully raised a total of $325M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $160.5 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $160.5M
-
First Round
First Round
(08 Dec 2017)
- Investors Count 25
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Series C - Obsidian Therapeutics | Valuation | Wellington | |
| Sep, 2021 | Amount | Series B - Obsidian Therapeutics | Valuation | TCG Crossover | |
| Dec, 2017 | Amount | Series A - Obsidian Therapeutics | Valuation | Google Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Obsidian Therapeutics
Obsidian Therapeutics has secured backing from 25 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, TD Securities and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Obsidian Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Obsidian Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Obsidian Therapeutics Comparisons
Competitors of Obsidian Therapeutics
Obsidian Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, Senti Biosciences, TScan Therapeutics and Vir Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Obsidian Therapeutics
Frequently Asked Questions about Obsidian Therapeutics
When was Obsidian Therapeutics founded?
Obsidian Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Obsidian Therapeutics located?
Obsidian Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Obsidian Therapeutics?
Michael Gilman is the current CEO of Obsidian Therapeutics.
Is Obsidian Therapeutics a funded company?
Obsidian Therapeutics is a funded company, having raised a total of $325M across 3 funding rounds to date. The company's 1st funding round was a Series A of $49.5M, raised on Dec 08, 2017.
How many employees does Obsidian Therapeutics have?
As of Dec 31, 2022, the latest employee count at Obsidian Therapeutics is 80.
What is the annual revenue of Obsidian Therapeutics?
Annual revenue of Obsidian Therapeutics is $639.91 as on Jul 31, 2023.
What does Obsidian Therapeutics do?
Obsidian Therapeutics is engaged in pioneering cell and gene therapy solutions. The company is recognized for leading the next generation of engineered therapeutics. Its proprietary cytoDRiVE platform is utilized to control protein function with FDA-approved small molecules. A novel pipeline of therapeutics is being developed, including the lead clinical program OBX-115 for advanced melanoma. Collaborations are established to enable discovery of innovative therapies. The focus is placed on precision medicines to address patient needs across various healthcare sectors.
Who are the top competitors of Obsidian Therapeutics?
Obsidian Therapeutics's top competitors include BeiGene, BioNTech and Senti Biosciences.
What products or services does Obsidian Therapeutics offer?
Obsidian Therapeutics offers OBX-115 and cytoDRiVE® Platform.
Who are Obsidian Therapeutics's investors?
Obsidian Therapeutics has 25 investors. Key investors include Amgen, TD Securities, Citadel, Janus Henderson Investors, and RTW Investments.